FDA Notice Of Proposed Rulemaking On Hydroquinone Slated For June
This article was originally published in The Rose Sheet
Executive Summary
The Center for Drug Evaluation & Research's Division of OTC Drug Products plans to publish a notice of proposed rulemaking on hydroquinone, a cosmetic ingredient frequently used in skin brightening products, in June, FDA reported in its unified regulatory agenda, published in a Dec. 13 Federal Register 1notice
You may also be interested in...
Rx Hydroquinone Skin Bleach Regulatory Controls Sought By Galderma
Galderma Labs calls for stricter FDA enforcement over unapproved marketed prescription drugs and new requirements for disclosure regarding the lack of approval in recent comments to the agency
Aspergillus Extract Could Offer New Skin Brightening Benefits - Lauder
Use of melanin degrading extracts isolated from aspergillus fumigatus may lead to the development of new brightening skin care products to even skin color and tone, Estee Lauder researchers conclude in a study presented at the Society of Cosmetic Chemists annual scientific meeting in New York City Dec. 4-5
Artificial Nail System Ingredients Approved By EU For Professional Use
Use of benzoyl peroxide, hydroquinone and hydroquinone methylether in artificial nail systems is permissible in a professional setting under an amendment to Annex III of the European Union Cosmetics Directive